Zaid Admani

The new model is already available on Meta's AI app, and it's gonna be rolling out on Instagram, WhatsApp, and the Meta smart glasses.

Zug seems to be going after the casual users here because he admitted that Spark isn't good at coding, which is something that ChatGPT and Claude are really good at.

But he also said that Meta is working on a more powerful model code named Watermelon that's gonna close the gap on coding as well.

So I'm looking forward to trying this model.

I mean, Meta has spent billions of dollars on AI, so I'm glad to see they've released something.

Now, I'm still not sure if all that AI CapEx is going to end up paying off, because I think it's going to take a lot for people to switch from ChatGPT and Claude to Meta's AI.

But look, Zuck is showing no signs of cutting back on AI spend.

In fact, Meta just announced a $21 billion AI cloud infrastructure deal with CoreWeave this morning.

This is on top of the $14 billion in commitments that the two sides have already agreed to.

By the way, Meta's stock jumped more than 6% yesterday, and it's gone up nearly 20% since its lows back on March 27th.

So shout out to everyone that bought the dip.

Let's shift gears and talk about Eli Lilly.

The pharma giant has officially launched its new GLP-1 weight loss pill called Foundeo.

Eli Lilly is the maker of the GLP-1 drugs Manjaro and Zepound.

They've become a massive hit over the last couple of years, pushing Eli Lilly's market cap to over a trillion dollars at one point.

But the downside for those drugs is that they are injections.

Like you have to give yourself a shot once a week and a lot of people don't like needles.

Foundeo is a once a daily pill and that should open up the market to a lot more patients.

Not to mention pills are a lot cheaper to manufacture compared to needles and injections.

Now, Eli Lilly isn't the first to market with a GLP-1 pill.